Is this you? Create Your Porfile
Avatar

N. Vargas Zea

Pfizer

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where N. Vargas Zea is active.

Explore More

Publication

Featured researches published by N. Vargas Zea.

Value in Health | 2014

Contribution Of Health Economics & Outcomes Research Studies Of Colombia To Ispor Conferences

M.V. Gutierrez-Ardila; N. Vargas Zea

Value in Health | 2013

Cost Effectiveness Analysis Of Vaccination With 13-Valent (Pcv13) And 23-Valent (Ppsv23) Pneumococcal Vaccines For Adults In A Private Colombian Institution

J.E. Ordoñez Molina; M.V. Gutierrez-Ardila; N. Vargas Zea

Value in Health | 2013

Cost Effectiveness Analysis Of Vaccination With 13-Valent (Pcv13) And 23-Valent (Ppsv23) Pneumococcal Vaccines For Adults In Bogota, Colombia – Public Scenario

J.E. Ordoñez Molina; M.V. Gutierrez-Ardila; N. Vargas Zea

Value in Health | 2014

Budget Impact Analysis Of Apixaban Versus Enoxaparin In Patients Undergoing Total Hip Or Knee Replacement In Colombia

J.E. Ordoñez Molina; S. Garrido Lecca; N. Vargas Zea; V. Prieto Martinez

Value in Health | 2014

Impact On Health Status And Disease Specific Quality Of Life Of Tofacitinib In Patients With Inadequate Response To Non-Biological Disease-Modifying Antirheumatic Drugs (Dmard) Versus Anti-Tumor Necrosis Factor Drugs (Anti-Tnf) In Colombia

J.J. Vargas-Valencia; N. Vargas Zea; M.V. Gutierrez-Ardila

Value in Health | 2014

Non Pharmacological Comparison Of Apixaban Versus Warfarin In The Treatment Of Patients With Non-Valvular Atrial Fibrillation

N. Vargas Zea; V. Prieto Martinez; S. Garrido Lecca

Value in Health | 2014

Functional Status And Labor Productivity With Tofacitinib In Patients With Inadequate Response To Non-Biological Disease-Modifying Antirheumatic Drugs (Dmard) Versus Anti-Tumor Necrosis Factor Drugs (Anti-Tnf) In Colombia

J.J. Vargas-Valencia; N. Vargas Zea; M.V. Gutierrez-Ardila

Value in Health | 2013

The cost-effectiveness of apixaban in venous thromboembolism prevention in patients undergoing elective total knee or hip replacement in the colombian private sector

J. Ordoñez; S. Garrido Lecca; N. Vargas Zea; A. Juarez Garcia; J.F. Mould; B.M.K. Donato

Value in Health | 2013

Budget Impact Analysis Of Linezolid In The Treatment Of Complicated Skin And Soft Tissue Infections In Colombia

O.D. Diaz-Sotelo; T. Barbosa Castro; A. Vecino Ortiz; N. Vargas Zea; J.F. Mould Quevedo; V. Prieto Martinez

Value in Health | 2013

Linezolid for the treatment of complicated skin and soft tissue infections (cssti) – A cost-effectiveness analysis for the chilean national fund of health

J.F. Mould-Quevedo; N. Vargas Zea; O.D. Diaz-Sotelo; V. Villamil Munevar; A. Vecino Ortiz

Explore More

Collaboration

Dive into the N. Vargas Zea's collaboration.

Top Co-Authors
Avatar

M.V. Gutierrez-Ardila

Pfizer

View shared research outputs
Top Co-Authors
Avatar

J.F. Mould-Quevedo

Pfizer

View shared research outputs
Top Co-Authors
Avatar

S. Garrido Lecca

Bristol-Myers Squibb

View shared research outputs
Top Co-Authors
Avatar

A. Vecino Ortiz

Johns Hopkins University

View shared research outputs
Top Co-Authors
Avatar

J.F. Mould

Pfizer

View shared research outputs
Top Co-Authors
Avatar

V. Prieto Martinez

Pfizer

View shared research outputs
Top Co-Authors
Avatar

J.E. Ordoñez Molina

University of Antioquia

View shared research outputs
Top Co-Authors
Avatar

A. Juarez Garcia

Bristol-Myers Squibb

View shared research outputs
Top Co-Authors
Avatar

B.M.K. Donato

Bristol-Myers Squibb

View shared research outputs
Top Co-Authors
Avatar

J.F. Mould Quevedo

Pfizer

View shared research outputs
Explore More
Researchain Logo
Decentralizing Knowledge